6.23+0.02+0.24%
03:59:50 PM EDT 9/13/2024BTT
Plus500. 82% of retail CFD accounts lose money
| News | Analyst Data | Analyst Opinions | Insider Activity | Dividend Calendar |
Best Online Brokers for Stock TradingWant to trade stocks and other assets? Don't lose hundreds of dollars in avoidable transaction costs! Discover the best brokers for stock trading and ordering other assets!
On Friday 09/13/2024 the closing price of the Voyager Therapeutics Inc share was $6.22 on BTT.Compared to the opening price on Friday 09/13/2024 on BTT of $6.26, this is a drop of 0.72%.Voyager Therapeutics Inc's market capitalization is $290.84 M by 54.53 M shares outstanding.
Is Voyager Therapeutics stock a Buy, Sell or Hold?
Voyager Therapeutics stock has received a consensus rating of buy. The average rating score is and is based on 9 buy ratings, 1 hold ratings, and 0 sell ratings.What was the 52-week low for Voyager Therapeutics stock?
The low in the last 52 weeks of Voyager Therapeutics stock was 6.01. According to the current price, Voyager Therapeutics is 103.66% away from the 52-week low.What was the 52-week high for Voyager Therapeutics stock?
The high in the last 52 weeks of Voyager Therapeutics stock was 12.29. According to the current price, Voyager Therapeutics is 50.69% away from the 52-week high.What are analysts forecasts for Voyager Therapeutics stock?
The 10 analysts offering price forecasts for Voyager Therapeutics have a median target of 18.20, with a high estimate of 30.00 and a low estimate of 8.00. The median estimate represents a 34.23 difference from the last price of 6.23.Voyager Therapeutics Stock Snapshot
6.23
Bid
200.00
Bid Size
6.24
Ask
302.00
Ask Size
9/13/2024
Date
3:59 PM
Time
14,710.00
Volume
6.22
Prev. Close
6.26
Open
342.99 M
Market Cap in USD
54.53 M
Number of Shares
6.14
Day Low
6.30
Day High
6.23
6.01
52 Week Low
12.29
52 Week High
6.23
0.00
Dividend in USD
0.00
Dividend Yield
2.84
P/E Ratio
82.84
Free Float in %
3.08
EPS in USD
5.37
Book Value per Share in USD
1.75
Cash Flow per Share in USD
Voyager Therapeutics NewsMore News
TipRanks
Voyager Therapeutics: A Strong Buy on Gene Therapy Prospects and Strategic Novartis Partnership
TipRanks
Truist Financial Sticks to Its Buy Rating for Voyager Therapeutics (VYGR)
RTTNews
Novartis Granted License For Novel Capsid Generated From Voyager's TRACER Capsid Discovery Platform
GlobeNewswire
Voyager Enters into License for Next-Generation Capsid, Bringing Partnered Portfolio of TRACER-Enabled Gene Therapies to 14
Historical Prices for Voyager Therapeutics
| Date | Open | Close | Daily High | Daily Low |
|---|
Price change over selected period:0%0
Voyager Therapeutics Analyst Data
Total Analysts: 10
Buy Ratings: 9 Neutral Ratings: 1 Sell Ratings: 0
Analyst: {{ANALYST_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price *Price Target
Lowest: 8.00 Median: 18.20 Highest: 30.00
*The average price target includes all analyst analysis, not just the most recent analysis presented in the chart.
Voyager Therapeutics Analyst Opinions
- All
- Buy
- Hold
- Sell
| Date | Analyst | Rating | Price | |||
|---|---|---|---|---|---|---|
| 05/16/24 | H.C. Wainwright & Co. | Maintained Buy | $30 | gut | ||
| 05/15/24 | Oppenheimer & Co. Inc. | Maintained Buy | $18 | gut | ||
| 05/14/24 | Wedbush Morgan Securities Inc. | Maintained Hold | $8 | neutral | ||
| 03/26/24 | Guggenheim | Maintained Buy | $22 | gut | ||
| 03/19/24 | H.C. Wainwright & Co. | Maintained Buy | $30 | gut | ||
| 03/07/24 | Citigroup Corp. | Maintained Buy | $16 | gut | ||
| 01/02/24 | Wells Fargo & Co | Upgraded to Buy | $14 | gut | ||
| 08/07/23 | Oppenheimer & Co. Inc. | Maintained Buy | $16 | gut | ||
| 05/10/23 | Capital Depesche | Maintained Buy | $14 | gut | ||
| 03/10/23 | Oppenheimer & Co. Inc. | Maintained Buy | $14 | gut |
Voyager Therapeutics Estimates* in USD
| 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|
| Revenue | 69 | 56 | 60 | 74 | 110 |
| Dividend | - | - | - | - | - |
| Dividend Yield (in %) | 0.00 % | 0.00 % | 0.00 % | - | - |
| EPS | -1.40 | -1.81 | -1.70 | -1.57 | -0.88 |
| P/E Ratio | -4.45 | -3.45 | -3.67 | -3.96 | -7.08 |
| EBIT | -98 | -131 | -139 | -148 | -116 |
| EBITDA | -82 | -116 | -125 | -118 | -145 |
| Net Profit | -81 | -116 | -125 | -138 | -110 |
| Net Profit Adjusted | -72 | -128 | -126 | -123 | -139 |
| Pre-Tax Profit | -81 | -116 | -125 | -138 | -110 |
| Pre-Tax Profit Reported | -92 | -165 | -174 | -198 | -206 |
| EPS (Non-GAAP) ex. SOE | -1.30 | -1.43 | -1.26 | -1.07 | -1.20 |
| EPS (GAAP) | -1.40 | -1.81 | -1.70 | -1.57 | -0.88 |
| Gross Income | 71 | 76 | 81 | 96 | 156 |
| Cash Flow from Investing | -98 | 28 | 67 | -9 | -10 |
| Cash Flow from Operations | -25 | -111 | -83 | -81 | -107 |
| Cash Flow from Financing | 113 | 92 | 100 | 171 | 71 |
| Cash Flow per Share | -0.68 | -1.61 | -1.14 | -0.94 | -1.07 |
| Free Cash Flow | -30 | -117 | -90 | -89 | -116 |
| Free Cash Flow per Share | -0.36 | -1.25 | -1.12 | -0.96 | -1.21 |
| Book Value per Share | 4.67 | 3.83 | 4.83 | 5.02 | 3.89 |
| Net Debt | -301 | -285 | -436 | -522 | -392 |
| Research & Development Exp. | 128 | 140 | 146 | 161 | 156 |
| Capital Expenditure | 6 | 6 | 8 | 9 | 10 |
| Selling, General & Admin. Exp. | 40 | 48 | 45 | 49 | 52 |
| Shareholder’s Equity | 289 | 271 | 326 | 407 | 360 |
| Total Assets | 383 | 347 | 394 | 484 | 444 |
| Previous Quarter ending 06/30/24 | Current Quarter ending 09/30/24 | Next Quarter ending 12/31/24 | Current Year ending 12/31/24 | Next Year ending 12/31/25 | |
|---|---|---|---|---|---|
| Earnings Estimates | |||||
| No. of Analysts | - | 9 | 9 | 9 | 9 |
| Average Estimate | - | -0.486 USD | -0.513 USD | -1.399 USD | -1.807 USD |
| Year Ago | - | -0.591 USD | 1.282 USD | 3.076 USD | - |
| Publish Date | - | 11/5/2024 | 3/11/2025 | - | - |
| Revenue Estimates | |||||
| No. of Analysts | - | 9 | 9 | 9 | 9 |
| Average Estimate | - | 10 USD | 10 USD | 69 USD | 56 USD |
| Year Ago | - | 5 USD | 90 USD | 250 USD | - |
| Publish Date | - | 11/5/2024 | 3/11/2025 | - | - |
* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet
Income Statements in Mio. USD
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Sales | 250.01 | 40.91 | 37.42 | 171.13 | 104.39 | 7.62 | 10.14 |
| Change of sales in % | 511.16 | 9.33 | -78.14 | 63.93 | 1,270.14 | -24.82 | -28.73 |
| Gross profit on sales | 245.57 | 34.72 | - | - | - | - | - |
| Gross profit on sales change in % | 607.36 | - | - | - | - | - | - |
| Operating income | 122.01 | -50.84 | -71.02 | 27.38 | -51.68 | -91.10 | -71.86 |
| Operating income change in % | - | 28.42 | - | - | 43.27 | -26.76 | -74.01 |
| Income before tax | 133.74 | -46.39 | -71.20 | 36.74 | -43.60 | -88.47 | -70.70 |
| Income before tax change in % | - | 34.84 | - | - | 50.72 | -25.14 | -76.12 |
| Income after tax | 132.33 | -46.41 | -71.20 | 36.74 | -43.60 | -88.29 | -70.70 |
| Income after tax change in % | - | 34.82 | - | - | 50.62 | -24.88 | -75.90 |
Balance Sheet in Mio. USD
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Total liabilities | 114.96 | 100.34 | 98.80 | 107.26 | 255.25 | 130.58 | 50.43 |
| Long-term liabilities per share | 1.15 | 0.72 | 1.26 | 2.15 | 4.86 | 3.06 | 1.09 |
| Equity | 236.32 | 59.02 | 95.06 | 154.32 | 99.51 | 46.45 | 134.05 |
| Equity change in % | 300.41 | -37.91 | -38.40 | 55.08 | 114.25 | -65.35 | -1.38 |
| Balance sheet total | 351.28 | 159.36 | 193.86 | 261.58 | 354.76 | 177.03 | 184.48 |
| Balance sheet total change in % | 120.44 | -17.80 | -25.89 | -26.26 | 100.40 | -4.04 | -2.68 |
Key Data in USD
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Sales per share | 5.61 | 1.07 | 0.99 | 4.58 | 2.91 | 0.24 | 0.38 |
| P/E ratio (year end quote, basic EPS) | 2.84 | - | - | 7.27 | - | - | - |
| P/E ratio (year end quote, diluted EPS) | 2.84 | - | - | 7.27 | - | - | - |
| P/E ratio (year end quote) | 2.84 | - | - | 7.27 | - | - | - |
| Dividend yield in % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Equity ratio in % | 67.27 | 37.04 | 49.03 | 58.99 | 28.05 | 26.24 | 72.67 |
| Debt ratio in % | 32.73 | 62.96 | 50.97 | 41.01 | 71.95 | 73.76 | 27.33 |
Voyager Therapeutics Insider Activity
| Name | Date | shares traded | shares held | Price | type (sell/buy) | option |
|---|---|---|---|---|---|---|
| Ferguson Toby | 03/31/2024 | 105,000.00 | 105,000.00 | n/a | Buy | No |
| PFREUNDSCHUH PETER P. | 02/20/2024 | 3,764.00 | 175,669.00 | 7.46 | Sell | No |
| Carter Todd Alfred | 02/20/2024 | 3,365.00 | 87,627.00 | 7.47 | Sell | No |
| Swartz Robin | 02/20/2024 | 3,966.00 | 118,361.00 | 7.45 | Sell | No |
| Sandrock Alfred | 02/20/2024 | 13,033.00 | 334,954.00 | 7.46 | Sell | No |
| Carter Todd Alfred | 02/19/2024 | 602.00 | 90,992.00 | 7.68 | Sell | No |
| Carter Todd Alfred | 02/08/2024 | 38,500.00 | 91,594.00 | n/a | Buy | No |
| Sandrock Alfred | 02/08/2024 | 130,000.00 | 347,987.00 | n/a | Buy | No |
| Swartz Robin | 02/08/2024 | 50,000.00 | 122,327.00 | n/a | Buy | No |
| Fahey Sandell Jacquelyn | 02/08/2024 | 31,000.00 | 92,000.00 | n/a | Buy | No |
| Swartz Robin | 01/16/2024 | 2,543.00 | 72,327.00 | 7.15 | Sell | No |
| Carter Todd Alfred | 01/16/2024 | 1,266.00 | 53,094.00 | 7.18 | Sell | No |
| PFREUNDSCHUH PETER P. | 10/02/2023 | 13,567.00 | 149,433.00 | 6.99 | Sell | No |
| Fahey Sandell Jacquelyn | 09/30/2023 | 61,000.00 | 61,000.00 | n/a | Buy | No |
| Carter Todd Alfred | 09/14/2023 | 10,500.00 | 54,360.00 | 8.16 | Sell | No |
| Carter Todd Alfred | 09/14/2023 | 5,000.00 | 64,860.00 | 2.85 | Buy | No |
| Carter Todd Alfred | 07/05/2023 | 5,500.00 | 59,860.00 | 10.80 | Sell | No |
| Carter Todd Alfred | 06/29/2023 | 5,000.00 | 65,360.00 | 11.41 | Sell | No |
| Carter Todd Alfred | 06/29/2023 | 5,000.00 | 70,360.00 | 2.85 | Buy | No |
| Sandrock Alfred | 04/02/2023 | 7,437.00 | 214,618.00 | 7.83 | Sell | No |
| Swartz Robin | 04/02/2023 | 1,259.00 | 71,617.00 | 7.83 | Sell | No |
| Carter Todd Alfred | 03/19/2023 | 2,193.00 | 65,360.00 | 7.76 | Sell | No |
| Hesslein Robert W. | 03/19/2023 | 4,410.00 | 102,200.00 | 7.76 | Sell | No |
| Swartz Robin | 03/19/2023 | 3,654.00 | 72,876.00 | 7.76 | Sell | No |
| Swartz Robin | 03/14/2023 | 15,373.00 | 76,530.00 | 8.20 | Sell | No |
Voyager Therapeutics Dividend Calendar
| Date | Name | Dividend | *yield | Currency |
|---|---|---|---|---|
| 2023 | Voyager Therapeutics Inc | 0.00 | 0.00 | USD |
| 2022 | Voyager Therapeutics Inc | 0.00 | 0.00 | USD |
| 2021 | Voyager Therapeutics Inc | 0.00 | 0.00 | USD |
| 2020 | Voyager Therapeutics Inc | 0.00 | 0.00 | USD |
| 2019 | Voyager Therapeutics Inc | 0.00 | 0.00 | USD |
| 2018 | Voyager Therapeutics Inc | 0.00 | 0.00 | USD |
| 2017 | Voyager Therapeutics Inc | 0.00 | 0.00 | USD |
| 2016 | Voyager Therapeutics Inc | 0.00 | 0.00 | USD |
| 2015 | Voyager Therapeutics Inc | 0.00 | 0.00 | USD |
| 2014 | Voyager Therapeutics Inc | - | - | USD |
| 2013 | Voyager Therapeutics Inc | - | - | USD |
*Yield of the Respective Date
Voyager Therapeutics Calendar
| Event | Estimate | Info | Date |
|---|---|---|---|
| Earnings Report | -0.486 USD | Q3 2024 Earnings Release | 11/05/2024 |
| Earnings Report | -0.514 USD | Q4 2024 Earnings Release | 03/11/2025 |
| Earnings Report | -0.565 USD | Q1 2025 Earnings Release | 05/13/2025 |
| Earnings Report | -0.463 USD | Q2 2025 Earnings Release | 08/07/2025 |
Voyager Therapeutics Past Events
| Event | Actual EPS | Info | Date |
|---|---|---|---|
| Earnings Report | -0.176 USD | Q2 2024 Earnings Release | 08/06/2024 |
| Earnings Report | 0.151 USD | Q4 2021 Earnings Release | 03/08/2022 |
Voyager Therapeutics Profile
Voyager Therapeutics, Inc. is a clinical-stage gene therapy company, which engages in the development of treatments for severe neurological diseases. Its pipeline of gene therapy programs includes VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01. The company was founded by Guang Ping Gao, Mark A. Kay, Krystof Bankiewicz, and Phillip Zamore in June 2013 and is headquartered in Lexington, MA.
Moody’s Daily Credit Risk Score
Risk
- Low
- Medium
- High
8
Moody’s Daily Credit Risk Score is a 1-10 score of a company’s credit risk, based on an analysis of the firm’sbalance sheet and inputs from the stock market. The score provides a forward-looking, one-year measure of creditrisk, allowing investors to make better decisions and streamline their work ow. Updated daily, it takes intoaccount day-to-day movements in market value compared to a company’s liability structure.
Voyager Therapeutics Shareholder
| Owner | in % |
|---|---|
| Freefloat | 82.84 |
| Neurocrine Biosciences, Inc. | 15.72 |
| Armistice Capital LLC | 9.54 |
| Armistice Capital LLC | 7.77 |
| EcoR1 Capital, LLC | 7.18 |
| EcoR1 Capital, LLC | 7.06 |
| TRV GP III LLC | 5.84 |
| Vanguard Group, Inc. (Subfiler) | 5.50 |
| The Vanguard Group, Inc. | 4.64 |
| Farallon Capital Management LLC | 4.20 |
| BlackRock Fund Advisors | 3.68 |
| State Street Corp. | 3.28 |
| Vanguard Total Stock Market ETF | 3.14 |
| Jeffrey Robert Jay, MBA | 2.94 |
| BlackRock Institutional Trust Co. NA | 2.93 |
Shareholder percentage totals can add to more than 100% because some holders are included in the free float.
